| Identification | Back Directory | [Name]
N-(4-iodophenyl)-5-nitrofuran-2-carboxamide | [CAS]
314054-00-7 | [Synonyms]
C-176
STING inhibitor 1
C-176 STING inhibitor
N-(4-iodophenyl)-5-nitro-2-furamide
N-(4-iodophenyl)-5-nitrofuran-2-carboxamide
2-Furancarboxamide, N-(4-iodophenyl)-5-nitro- | [Molecular Formula]
C11H7IN2O4 | [MDL Number]
MFCD00784208 | [MOL File]
314054-00-7.mol | [Molecular Weight]
358.09 |
| Chemical Properties | Back Directory | [Boiling point ]
361.2±37.0 °C(Predicted) | [density ]
1.935±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
Soluble in DMSO (up to 25 mg/ml) | [form ]
solid | [pka]
11.14±0.70(Predicted) | [color ]
Brown or yellow | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
C-176 (314054-00-7) is an inhibitor of the signaling molecule STING in mouse cells. It covalently binds to Cys91 of STING preventing activation?via?blockade of palmitoylation at Cys91. Treatment of Trex-/-?mice with C-176 resulted in a significant reduction in serum levels of Type I Interferons and amelioration of systemic inflammation. | [Uses]
C-176 is a selective and blood-brain barrier permeable STING inhibitor. C-176 covalently targets transmembrane cysteine residue 91 and thereby blocking activation-induced palmitoylation of STING[1][2]. | [in vivo]
C-176 (750/375 nmol C-176 per mouse in 200 μL corn oil) significantly reduces the CMA-mediated induction of serum levels of type I IFNs and IL-6., without significant toxicity[1].
C-176 results in a significant reduction in serum levels of type I IFNs and in a strong suppression of inflammatory parameters in the heart, with no evident signs of overt toxicity Trex1 / mice[1].
C-176 demonstrates marked amelioration of various signs of systemic inflammation in Trex1 / mice[1].
| Animal Model: | WT type mice. | | Dosage: | 750/375 nmol C-176 per mouse in 200 μL corn oil (~1.34/0.67 mg/mL). | | Administration: | Intraperitoneally, once. | | Result: | Significantly reduced Serum levels of type I IFNs and IL-6. |
| [storage]
Store at -20°C | [References]
1)Haag?et al.?(2018),?Targeting STING with covalent small-molecule inhibitors; Nature?559?269 |
|
|